How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,649 results for

Thyroid Function Summary

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Thyroid Ultrasound Elasticity (TrUE) Imaging

): Stanislav Emelianov, Emory University Study Details Study Description Go to Brief Summary: In this study the researchers will scan the thyroid nodules of patients scheduled for surgical removal of these nodules. During their preadmission testing, but prior to their surgery, the researchers will perform standard ultrasound and shear wave elasticity imaging (SWEI) scans of the thyroid nodules in these patients. Both images can be generated by the same ultrasound scanner and within the same imaging session (...) Thyroid Ultrasound Elasticity (TrUE) Imaging Thyroid Ultrasound Elasticity (TrUE) Imaging - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Thyroid Ultrasound Elasticity (TrUE) Imaging The safety

2017 Clinical Trials

122. Efficacy of Dexmedetomidine for Cough Suppression in Patients Undergoing Thyroid Surgery

table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: 30Kg/m2 ≥ BMI > 18Kg/m2; undergoing general anesthesia; ASA physical status I and II undergoing elective thyroid surgery. Exclusion Criteria: hyperthyroidism; preoperative bradycardia; liver function impairment; renal function impairment; heart function failure; history of asthma or COPD; history of diabetes (...) Efficacy of Dexmedetomidine for Cough Suppression in Patients Undergoing Thyroid Surgery Efficacy of Dexmedetomidine for Cough Suppression in Patients Undergoing Thyroid Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2017 Clinical Trials

123. Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider

2017 Clinical Trials

124. The Feasibility and Safety of the TOETVA for Benign Thyroid Nodules

: The University of Hong Kong Information provided by (Responsible Party): Dr. Lang Hung Hin, Brian, The University of Hong Kong Study Details Study Description Go to Brief Summary: Thyroid surgery has been developed as a new technique for zero scar in surgery by applying transoral endoscopic thyroidectomy with sublingual approach. The new technique is locating the surgery which pierced through floor of mouth, cause severe tissue damage, high complication, and conversion rates to open surgery and surgical (...) after surgery The hematoma rate after TOETVA [ Time Frame: 12 months ] To record the situation of hematoma after surgery The vocal cord palsy rate after TOETVA [ Time Frame: 12 months ] To calculate the vocal cord situation after surgery within 12 months The hypoparathyroidism rate after TOETVA [ Time Frame: 12 months ] To record the thyroid function from blood test in 12 months after surgery and calculate the rate of hypo-parathyroid function The pain score of patient after TOETVA [ Time Frame: 12

2017 Clinical Trials

125. Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03122496 Recruitment Status : Recruiting

2017 Clinical Trials

126. UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

to Brief Summary: This is a Phase 2 Study of Everolimus and Lenvatinib in patients with metastatic differentiated thyroid cancer who have progressed on lenvatinib alone. Patient will have imaging, lab test and physical exams Condition or disease Intervention/treatment Phase Thyroid Cancer Drug: Lenvatinib Drug: Everolimus Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Intervention Model: Single Group (...) UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2017 Clinical Trials

127. Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy.

, there was curiosity to understand and learn the association of this disorder with another common endocrine gland function that is thyroid gland . The association between these two disorders has long been recognized although the prevalence of thyroid dysfunction in diabetic population varies widely between studies. With insulin and thyroid hormone being intimately involved in cellular metabolism and thus excess or deficit of these hormones result in functional derangement of the other . Diabetic patients have (...) factor for development of diabetic nephropathy. Condition or disease Evaluation Thyroid Functions in Diabetic Patient Detailed Description: Recognition and treatment of thyroid dysfunction in diabetic patients will benefit glycemic control and improve general well-being Diabetic nephropathy, a major microvascular complication of type 2 diabetes mellitus, is an important cause of chronic kidney disease. It results from interactions between hemodynamic and metabolic factors. Study Design Go to Layout

2017 Clinical Trials

128. RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Kettering Cancer Center Collaborators: AstraZeneca MedImmune LLC Information provided by (Responsible Party): Memorial Sloan Kettering Cancer Center Study Details Study Description Go to Brief Summary: The purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer. Durvalumab is a drug that has been developed to activate the immune system by blocking a protein called programmed death ligand-1 (...) RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. RAI Plus Immunotherapy

2017 Clinical Trials

129. Evaluation of the Pattern of Thyroid Dysfunctions in Patients With Metabolic Syndrome

, 2017 Last Update Posted : July 3, 2018 See Sponsor: Assiut University Information provided by (Responsible Party): GAAbdelhay, Assiut University Study Details Study Description Go to Brief Summary: The study on evaluation the pattern of TD in MetS population may help us to know the magnitude of overlap of these two disease entities and may highlight the importance of thyroid function tests in patients with MetS. This can lead to proper planning and adequate management strategies, resulting (...) , lipids and protein metabolism. These hormones accelerate metabolic processes and may be associated with metabolic syndrome. Hyperthyroidism is usually associated with low cholesterol and glucose intolerance; whereas hypothyroidism is associated with high cholesterol tendency, and patients are prone to weight gain and cardiac signs like bradycardia. Thyroid functions affect the components of MetS including HDLcholesterol (HDL-C), triglycerides (TG), blood pressure and plasma glucose. Thyroid

2017 Clinical Trials

130. Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean

2017 Clinical Trials

131. Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03085056 Recruitment Status : Recruiting First Posted : March 21

2017 Clinical Trials

132. Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

: Recruiting First Posted : May 30, 2017 Last Update Posted : May 30, 2017 See Sponsor: Tianjin Medical University Cancer Institute and Hospital Information provided by (Responsible Party): Tianjin Medical University Cancer Institute and Hospital Study Details Study Description Go to Brief Summary: This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with with locally advanced or metastatic differentiated thyroid carcinoma (DTC). The purpose of this study is to evaluate (...) Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2017 Clinical Trials

133. Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

: NCT03099356 Recruitment Status : Recruiting First Posted : April 4, 2017 Last Update Posted : June 6, 2018 See Sponsor: University of Michigan Rogel Cancer Center Information provided by (Responsible Party): University of Michigan Rogel Cancer Center Study Details Study Description Go to Brief Summary: This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1 (...) Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2017 Clinical Trials

134. Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF)

within the past 2 weeks. Scheduled cardiac resynchronization therapy or heart transplantation. History of malignant tumor or life expectancy under 12 months. Already on medications that may affect thyroid function (L-T4, carbimazole, propylthiouracil, amiodarone, lithium). Pregnancy and lactation period. Participation in another clinical trial within the past 30 days. Contraindication or intolerance to evidence-based therapy for CHF, such as beta-blocker, angiotensin-converting enzyme inhibitor (...) Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF) Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2017 Clinical Trials

135. Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer

Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2017 Clinical Trials

136. Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas

Recruitment Status : Recruiting First Posted : June 8, 2017 Last Update Posted : March 5, 2019 See Sponsor: M.D. Anderson Cancer Center Collaborator: Genentech, Inc. Information provided by (Responsible Party): M.D. Anderson Cancer Center Study Details Study Description Go to Brief Summary: Objectives: Primary To determine if targeted therapy + atezolizumab (cohorts 1-3) will lead to improved overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Secondary To evaluate the safety (...) Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2017 Clinical Trials

137. A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Sponsor: Dana-Farber Cancer Institute Collaborator: Genentech, Inc. Information provided by (Responsible Party): Mark Awad, MD, Dana-Farber Cancer Institute Study Details Study Description Go to Brief Summary: This research trial is studying a drug called alectinib as a possible treatment for non-small cell lung cancer (NSCLC) with specific genetic alterations known as ALK or RET rearrangements, and thyroid cancer with RET rearrangements. Condition or disease Intervention/treatment Phase ALK-positive (...) A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

138. Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.

: Recruiting First Posted : April 25, 2017 Last Update Posted : May 4, 2017 See Sponsor: Jena University Hospital Collaborator: GE Healthcare Information provided by (Responsible Party): Jena University Hospital Study Details Study Description Go to Brief Summary: Regular thyroid diagnostics versus augmented thyroid work-up with additional I-124 PET/US fusion for metabolic-sonographic nodule allocation in patients with benign thyroid diseases Condition or disease Intervention/treatment Thyroid Nodule (...) to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography. Regular Thyroid Work-up and I-124 PET/US Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124

2017 Clinical Trials

139. HOTAIR is a promising novel biomarker in patients with thyroid cancer (PubMed)

and development. One of the best-described lncRNAs, HOX transcript antisense RNA (HOTAIR), functions as a regulatory molecule in a wide variety of biological processes, and represses gene expression through recruitment of the chromatin modifying complex. However, the function of HOTAIR in TC remains unclear. In the current study, the expression of HOTAIR is elevated in TC and correlates with metastasis and poor prognosis. Furthermore, the expression of HOTAIR is significantly upregulated in human thyroid (...) carcinoma cells compared with normal human thyroid cells. Furthermore, knockdown of HOTAIR significantly inhibited cell growth and invasion in TPC-1 and SW579 human thyroid carcinoma. In summary, HOTAIR is a promising novel biomarker in patients with TC.

Full Text available with Trip Pro

2017 Experimental and therapeutic medicine

140. Predictors of a follicular nodule (Thy3) outcome of thyroid fine needle aspiration cytology among Saudi patients (PubMed)

Predictors of a follicular nodule (Thy3) outcome of thyroid fine needle aspiration cytology among Saudi patients A retrospective study was performed to evaluate predictors of thyroid fine needle aspiration cytology (FNAC) outcomes among Saudis with a thyroid nodule. Socio-demographic data, thyroid function status, thyroid parameters, ultrasound and cytology results were collected from 269 files of patients with thyroid nodules.The patients' age was 40 ± 1.4 years (mean ± SD), and the mean body (...)  = 0.039), respectively]. In summary, younger age, multinodular goitre, the absence of an irradiation history and cervical lymphadenopathy were protective against Thy3 in a thyroid nodule.

Full Text available with Trip Pro

2017 BMC research notes

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>